Published in Am J Gastroenterol on August 24, 2010
Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin. J Gastroenterol (2015) 2.03
Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc (2015) 1.53
The risks of PPI therapy. Nat Rev Gastroenterol Hepatol (2012) 0.94
Clopidogrel and proton pump inhibitors--where do we stand in 2012? World J Gastroenterol (2012) 0.85
Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy (2012) 0.84
Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart (2015) 0.83
Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial. Trials (2016) 0.81
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke (2015) 0.80
Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. Dig Dis Sci (2011) 0.77
PPIs and clopidogrel: the band plays on............ Am J Gastroenterol (2010) 0.76
Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts. J Gastroenterol (2013) 0.75
Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil (2012) 7.24
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology (2011) 6.36
The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil (2014) 4.69
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57
Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc (2010) 2.38
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol (2007) 2.26
Effects of anti-reflux surgery on weakly acidic reflux and belching. Gut (2010) 2.25
Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc (2009) 2.23
Safety of endoscopic removal of self-expandable stents after treatment of benign esophageal diseases. Gastrointest Endosc (2013) 2.22
In vitro evaluation of the radial and axial force of self-expanding esophageal stents. Endoscopy (2013) 2.18
Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Gastrointest Endosc (2007) 2.18
Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther (2006) 2.07
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet (2004) 2.06
Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut (2011) 2.03
Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc (2009) 1.97
Neoplasia yield and colonoscopic workload of surveillance regimes for colorectal cancer in colitis patients: a retrospective study comparing the performance of the updated AGA and BSG guidelines. Inflamm Bowel Dis (2013) 1.96
A prospective cohort study evaluating a novel colonoscopy platform featuring full-spectrum endoscopy. Endoscopy (2013) 1.95
Removable self-expanding plastic esophageal stent as a continuous, non-permanent dilator in treating refractory benign esophageal strictures: a prospective two-center study. Am J Gastroenterol (2008) 1.92
Esophageal acid exposure decreases intraluminal baseline impedance levels. Am J Gastroenterol (2011) 1.91
Systematic review and meta-analysis of laparoscopic Nissen (posterior total) versus Toupet (posterior partial) fundoplication for gastro-oesophageal reflux disease. Br J Surg (2010) 1.85
PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil (2012) 1.80
Electrocautery therapy for refractory anastomotic strictures of the esophagus. Gastrointest Endosc (2006) 1.76
Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology (2014) 1.75
Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch (2005) 1.74
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut (2011) 1.74
Determinants of perception of heartburn and regurgitation. Gut (2005) 1.69
ERCP as an outpatient treatment: a review. Gastrointest Endosc (2008) 1.68
Biomarkers of oxidative stress and risk of developing colorectal cancer: a cohort-nested case-control study in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol (2012) 1.65
High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol (2008) 1.64
Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest Endosc (2004) 1.64
Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2012) 1.64
Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol (2009) 1.60
Is complicated gallstone disease preceded by biliary colic? J Gastrointest Surg (2008) 1.59
Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc (2005) 1.58
Plasma alkylresorcinols, biomarkers of whole-grain wheat and rye intake, and incidence of colorectal cancer. J Natl Cancer Inst (2013) 1.57
Ingestion of acid and alkaline agents: outcome and prognostic value of early upper endoscopy. Gastrointest Endosc (2004) 1.57
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am J Gastroenterol (2008) 1.51
Fully covered self-expandable metal stents (SEMS), partially covered SEMS and self-expandable plastic stents for the treatment of benign esophageal ruptures and anastomotic leaks. BMC Gastroenterol (2012) 1.50
Rising incidence of clinically evident Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol (2007) 1.49
Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc (2010) 1.49
A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc (2009) 1.47
Reduced medication dependency and improved symptoms and quality of life 12 months after enteryx implantation for gastroesophageal reflux. J Clin Gastroenterol (2005) 1.46
Objective definition and detection of transient lower esophageal sphincter relaxation revisited: is there room for improvement? Neurogastroenterol Motil (2011) 1.46
No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis (2009) 1.46
Aerophagia, gastric, and supragastric belching: a study using intraluminal electrical impedance monitoring. Gut (2004) 1.43
Predictors of objectively identified recurrent reflux after primary Nissen fundoplication. Br J Surg (2011) 1.42
Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol (2007) 1.42
Nurses working in GI and endoscopic practice: a review. Gastrointest Endosc (2007) 1.42
Simulation of a colorectal polypoid lesion--a pilot porcine model. Gastrointest Endosc (2008) 1.39
[Therapy-resistant gastro-oesophageal reflux disease: endoluminal treatment not yet sufficiently compared with the gold standard, the laparoscopic Nissen fundoplication]. Ned Tijdschr Geneeskd (2008) 1.38
Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci (2013) 1.38
Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol (2013) 1.35
New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol (2007) 1.34
Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care (2003) 1.34
Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut (2012) 1.32
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis (2013) 1.31
Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut (2005) 1.29
Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut (2006) 1.28
Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer (2011) 1.27
Normal values for solid-state esophageal high-resolution manometry in a European population; an overview of all current metrics. Neurogastroenterol Motil (2014) 1.24
Fruit and vegetable consumption and mortality: European prospective investigation into cancer and nutrition. Am J Epidemiol (2013) 1.22
Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogastroenterol Motil (2012) 1.22
Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol (2008) 1.21
Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European ppulations. Cancer Epidemiol Biomarkers Prev (2012) 1.20
Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta (2010) 1.20
Plastic or metal stents for benign extrahepatic biliary strictures: a systematic review. BMC Gastroenterol (2009) 1.20
Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol (2011) 1.19
A new esophageal stent design (Niti-S stent) for the prevention of migration: a prospective study in 42 patients. Gastrointest Endosc (2006) 1.18
Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer (2012) 1.18
Endoscopic management of difficult or recurrent esophageal strictures. Am J Gastroenterol (2011) 1.18
Photodynamic therapy for Barrett's esophagus: not yet ready for the premier league of endoscopic interventions. Gastrointest Endosc (2005) 1.17
Esophageal stents for malignant strictures close to the upper esophageal sphincter. Gastrointest Endosc (2007) 1.16
Social inequalities and mortality in Europe--results from a large multi-national cohort. PLoS One (2012) 1.16
Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol (2006) 1.12
A labelled discrete choice experiment adds realism to the choices presented: preferences for surveillance tests for Barrett esophagus. BMC Med Res Methodol (2009) 1.11
Comparison of standard forward-viewing mode versus ultrawide-viewing mode of a novel colonoscopy platform: a prospective, multicenter study in the detection of simulated polyps in an in vitro colon model (with video). Gastrointest Endosc (2013) 1.10
Conversion of metaplastic Barrett's epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis Model Mech (2010) 1.10
Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2011) 1.09
A new fully covered metal stent for the treatment of benign and malignant dysphagia: a prospective follow-up study. Gastrointest Endosc (2012) 1.09
Birch pollen sensitization with cross-reactivity to food allergens predominates in adults with eosinophilic esophagitis. Allergy (2013) 1.09
A modified self-expanding Niti-S stent for the management of benign hypopharyngeal strictures. Gastrointest Endosc (2007) 1.09
[Quality indicators for colonoscopy: differences in polyp detection between endoscopists at one hospital]. Ned Tijdschr Geneeskd (2012) 1.08
Dynamic contrast-enhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. AJR Am J Roentgenol (2006) 1.08
Fruit and vegetable intake and the risk of gastric adenocarcinoma: a reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study after a longer follow-up. Int J Cancer (2012) 1.08
Slide preparation for single-cell-resolution imaging of fluorescent proteins in their three-dimensional near-native environment. Nat Protoc (2011) 1.07
Assessment of oesophageal motor function using combined perfusion manometry and multi-channel intra-luminal impedance measurement in normal subjects. Neurogastroenterol Motil (2005) 1.05
Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int (2009) 1.05
High acquisition and environmental contamination rates of CC17 ampicillin-resistant Enterococcus faecium in a Dutch hospital. J Antimicrob Chemother (2008) 1.04
The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther (2002) 1.04
Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis (2015) 1.04